

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Inform	ation						
1. Given Name (First Name) Robert	2. Surname (Last Name) 3. Date Stockley 15-April-2020						
4. Are you the corresponding author?	✓ Yes	No					
5. Manuscript Title Alpha-1Antitrypsin deficiency: the learn	ing goes (on					
6. Manuscript Identifying Number (if you kn Blue-202004-0922ED	ow it)						
Section 2. The Work Under Co							
The Work Under Co	onsidera [®]	tion for P	ublication				
Did you or your institution at any time recei- any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not lin	nited to grar				c.) for	
Section 3. Relevant financial a	activities	outside	the submitted	work.			
Place a check in the appropriate boxes in of compensation) with entities as descril clicking the "Add +" box. You should rep Are there any relevant conflicts of intere If yes, please fill out the appropriate info	n the table ped in the ort relationst?	e to indicat instruction onships tha Yes	e whether you hans. Use one line fo	ave financ or each er	ntity; add as many lines as you need	d by	
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
AstraZeneca		✓			Advisory board membership and payment for lectures		
Nycomed		\checkmark			Payment for lectures		
CSL Behring	✓	✓			Advisory board membership and payment for lectures and travel to meetings. Noncommercial Investigator lead research project		
Kamada		✓			Advisory board membership and DSMB for Phase 3 study		
Baxter		\checkmark		\checkmark	Advisory board membership. Funding support for research assays		



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments				
Polyphor		✓			Advisory board membership				
GlaxoSmithKline		√			Payment for lectures				
Z Factor		\checkmark			Steering Committee Chair				
Vertex		\checkmark			Advisory board membership				
Mereo Biopharma	✓	✓			CI for phase 2 studies and Investigator lead research funding				
Section 4. Intellectual Propert	·	-		ma a a ab o	work? Vos. V No.				
Do you have any patents, whether plann	ea, pena	ing or issue	ed, broadly releva	nt to the	work? Yes ✓ No				
Section 5. Relationships not c	overed	above							
Are there other relationships or activities potentially influencing, what you wrote i				influence	d, or that give the appearance of				
Yes, the following relationships/cond	litions/cir	cumstance	es are present (exp	olain belo	ow):				
✓ No other relationships/conditions/circumstances that present a potential conflict of interest									
At the time of manuscript acceptance, jo On occasion, journals may ask authors to					•	ents.			
Section 6. Disclosure Stateme	nt								
Based on the above disclosures, this form below.	n will auto	omatically (generate a disclos	sure state	ement, which will appear in the box				
Dr. Stockley reports personal fees from A Behring, personal fees from Kamada, per GlaxoSmithKline, personal fees from Z Footside the submitted work; .	rsonal fee	s and othe	r from Baxter, pei	rsonal fee	es from Polyphor, personal fees from	1			



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.